Jpmorgan Chase & CO Syndax Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

$1.51 Trillion
Q3 2025

A detailed history of Jpmorgan Chase & CO transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 253,850 shares of SNDX stock, worth $4.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

253,850

Previous 1,105,807 77.04%

Holding current value

$4.5 Million

Previous $13.6 Million 71.26%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	SELL	$8.73 - $17.04 $7.44 Million - $14.5 Million	-851,957 Reduced 77.04%	253,850 $3.91 Million
Q1 2025 May 12, 2025	BUY	$12.29 - $16.38 $2.56 Million - $3.42 Million	208,490 Added 23.23%	1,105,807 $13.6 Million
Q4 2024 Feb 12, 2025	BUY	$12.52 - $21.81 $3.38 Million - $5.88 Million	269,638 Added 42.96%	897,317 $11.9 Million
Q3 2024 Dec 26, 2024	SELL	$17.93 - $24.81 $39,463 - $54,606	-2,201 Reduced 0.35%	627,679 $12.1 Million
Q3 2024 Nov 08, 2024	SELL	$17.93 - $24.81 $39,463 - $54,606	-2,201 Reduced 0.35%	627,679 $12.1 Million
Q2 2024 Dec 26, 2024	BUY	$18.82 - $23.79 $41,422 - $52,361	2,201 Added 0.35%	629,880 $12.9 Million
Q2 2024 Aug 12, 2024	SELL	$18.82 - $23.79 $989,630 - $1.25 Million	-52,584 Reduced 7.71%	629,880 $12.9 Million
Q1 2024 Dec 26, 2024	BUY	$19.71 - $24.57 $1.08 Million - $1.35 Million	54,785 Added 8.73%	682,464 $16.2 Million
Q1 2024 May 10, 2024	SELL	$19.71 - $24.57 $1.94 Million - $2.42 Million	-98,466 Reduced 12.61%	682,464 $16.2 Million
Q4 2023 Dec 26, 2024	BUY	$11.39 - $21.67 $1.75 Million - $3.32 Million	153,251 Added 24.42%	780,930 $16.9 Million
Q4 2023 Feb 12, 2024	BUY	$11.39 - $21.67 $590,366 - $1.12 Million	51,832 Added 7.11%	780,930 $16.9 Million
Q3 2023 Nov 14, 2023	SELL	$14.52 - $21.77 $604,365 - $906,132	-41,623 Reduced 5.4%	729,098 $10.6 Million
Q2 2023 Aug 11, 2023	BUY	$19.35 - $22.31 $4.29 Million - $4.94 Million	221,636 Added 40.36%	770,721 $16.1 Million
Q1 2023 May 18, 2023	BUY	$20.66 - $28.98 $1.61 Million - $2.25 Million	77,776 Added 16.5%	549,085 $11.6 Million
Q1 2023 May 11, 2023	SELL	$20.66 - $28.98 $1.38 Million - $1.94 Million	-66,817 Reduced 12.42%	471,309 $9.95 Million
Q4 2022 Feb 13, 2023	SELL	$20.64 - $26.24 $1.61 Million - $2.05 Million	-78,125 Reduced 12.68%	538,126 $13.7 Million
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $406,275 - $544,115	21,949 Added 3.69%	616,251 $14.8 Million
Q2 2022 Aug 11, 2022	BUY	$13.64 - $19.48 $4.84 Million - $6.91 Million	354,473 Added 147.8%	594,302 $11.4 Million
Q1 2022 May 11, 2022	BUY	$14.84 - $22.15 $1.03 Million - $1.54 Million	69,356 Added 40.68%	239,829 $4.17 Million
Q4 2021 Feb 10, 2022	BUY	$15.23 - $22.47 $1.45 Million - $2.15 Million	95,491 Added 127.35%	170,473 $3.73 Million
Q3 2021 Nov 12, 2021	BUY	$13.87 - $19.8 $1.04 Million - $1.48 Million	74,982 New	74,982 $1.43 Million

Others Institutions Holding SNDX

# of Institutions

255

Shares Held

101M

Call Options Held

1.22M

Put Options Held

1.24M

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $1B
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Syndax Pharmaceuticals Inc Transaction History